Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L M Aledort

Showing results (51-60 of 187) with videos related to

Pageof 19
Sort By:
Scandinavian Journal of Haematology. Supplementum|January 1, 1977
World use of blood products for hemophiliaL M Aledort
Seminars in Thrombosis and Hemostasis|January 1, 1976
Platelets and thromboembolismL M Aledort
The New England Journal of Medicine|March 11, 1982
Lessons from hemophiliaL M Aledort
Annals of the New York Academy of Sciences|January 1, 1987
Factor VIII/von Willebrand factor replacement therapy. Problems and challengesL M Aledort
Haemophilia : the Official Journal of the World Federation of Hemophilia|January 3, 2001
Issues in making a therapeutic choice: recombinant and/or human-derived productsL M Aledort
Seminars in Thrombosis and Hemostasis|August 5, 2000
Factor VIII inhibitors. Immune tolerance induction: is it cost effective? We know too littleL M Aledort
Thrombosis and Haemostasis|May 24, 2000
Recombinant factor VIIa is a pan-hemostatic agent?L M Aledort
Haemophilia : the Official Journal of the World Federation of Hemophilia|October 27, 2007
Factor VIII inhibitor bypassing activity (FEIBA) - addressing safety issuesL M Aledort
Journal of Thrombosis and Haemostasis : JTH|October 31, 2009
To bleed or not to bleed - is that a question?L M Aledort
Journal of Thrombosis and Haemostasis : JTH|May 14, 2004
Is the incidence and prevalence of inhibitors greater with recombinant products? YesL M Aledort
Pageof 19

Showing results (51-60 of 187) with videos related to

Sort By:
Pageof 19
Scandinavian Journal of Haematology. Supplementum|January 1, 1977
World use of blood products for hemophiliaL M Aledort
Seminars in Thrombosis and Hemostasis|January 1, 1976
Platelets and thromboembolismL M Aledort
The New England Journal of Medicine|March 11, 1982
Lessons from hemophiliaL M Aledort
Annals of the New York Academy of Sciences|January 1, 1987
Factor VIII/von Willebrand factor replacement therapy. Problems and challengesL M Aledort
Haemophilia : the Official Journal of the World Federation of Hemophilia|January 3, 2001
Issues in making a therapeutic choice: recombinant and/or human-derived productsL M Aledort
Seminars in Thrombosis and Hemostasis|August 5, 2000
Factor VIII inhibitors. Immune tolerance induction: is it cost effective? We know too littleL M Aledort
Thrombosis and Haemostasis|May 24, 2000
Recombinant factor VIIa is a pan-hemostatic agent?L M Aledort
Haemophilia : the Official Journal of the World Federation of Hemophilia|October 27, 2007
Factor VIII inhibitor bypassing activity (FEIBA) - addressing safety issuesL M Aledort
Journal of Thrombosis and Haemostasis : JTH|October 31, 2009
To bleed or not to bleed - is that a question?L M Aledort
Journal of Thrombosis and Haemostasis : JTH|May 14, 2004
Is the incidence and prevalence of inhibitors greater with recombinant products? YesL M Aledort
Pageof 19